ADMA Biologics Earns BioNJ 2020 Innovator Award for Primary Immunodeficiency Treatment
source: pixabay.com

ADMA Biologics Earns BioNJ 2020 Innovator Award for Primary Immunodeficiency Treatment

According to a story from gurufocus.com, the biopharmaceutical company ADMA Biologics, Inc., has earned the 2020 BioNJ Innovator Award. This award was given as acknowledgement of the company's successful development…

Continue Reading ADMA Biologics Earns BioNJ 2020 Innovator Award for Primary Immunodeficiency Treatment
A Pilot DNA Therapy for Recurrent Respiratory Papillomatosis (RRP) Shows Promising Results
source: pixabay.com

A Pilot DNA Therapy for Recurrent Respiratory Papillomatosis (RRP) Shows Promising Results

As originally reported in BioPortfolio, a novel DNA therapy for patients with HPV 6 who experience recurrent respiratory papillomatosis (RRP) has concluded its first clinical trial with promising results. As…

Continue Reading A Pilot DNA Therapy for Recurrent Respiratory Papillomatosis (RRP) Shows Promising Results
Researchers Have Found New Causes of Angiosarcoma and 3 Trials are Underway
source: pixabay.com

Researchers Have Found New Causes of Angiosarcoma and 3 Trials are Underway

Angiosarcoma Angiosarcoma is a rare condition caused by a tumor within the endothelial cells. These cells line the blood vessels in the body, and therefore the tumors can occur practically…

Continue Reading Researchers Have Found New Causes of Angiosarcoma and 3 Trials are Underway
An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit
source: pixabay.com

An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit

  On February 3, 2020, twenty-seven newly installed flags of the European Union stood in the gleaming lobby of the new European Medicines Agency (EMA) headquarters in Amsterdam. The Charcot-Marie-Tooth…

Continue Reading An In-Depth Look at the European Medicines Agency’s Orphan Drug Designation Post-Brexit
Expanding AAV Manufacturing Capacity is Essential to Our Ability to Cure More Patients Living with Rare Disease
source: pixabay.com

Expanding AAV Manufacturing Capacity is Essential to Our Ability to Cure More Patients Living with Rare Disease

  The National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and the Center for Biologics Evaluation and Research (CBER) of the Food and Drug…

Continue Reading Expanding AAV Manufacturing Capacity is Essential to Our Ability to Cure More Patients Living with Rare Disease